British Journal of Haematology最新文献

{"title":"In a nutshell: Haematological immune-related adverse events","authors":"Rebecca K. Leaf,&nbsp;Jodi V. Mones","doi":"10.1111/bjh.70782","DOIUrl":"10.1111/bjh.70782","url":null,"abstract":"<div>\u0000 \u0000 <p>The use of immune checkpoint inhibitors (ICIs) have transformed oncological care. In this ‘nutshell review’, we summarize the most common haematological immune-related adverse events (irAEs) associated with checkpoint inhibitors. We also outline management strategies and address current evidence regarding ICI rechallenge.</p>\u0000 </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"209 5","pages":"2007-2010"},"PeriodicalIF":3.6,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148811595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SENIOR-IPI: An easily applicable prognostic index for first-line large B-cell lymphomas patients >80 years treated with curative intent","authors":"Sydney Dubois,&nbsp;Fanny Cherblanc,&nbsp;Aurelien Belot,&nbsp;Lucie Oberic,&nbsp;Hervé Ghesquières,&nbsp;Corinne Haioun,&nbsp;Hervé Tilly,&nbsp;Jean-Philippe Jais,&nbsp;Fabrice Jardin","doi":"10.1111/bjh.70784","DOIUrl":"10.1111/bjh.70784","url":null,"abstract":"<p>Using LYmphoma Study Association clinical trials combining 438 first-line large B-cell lymphomas (LBCL) patients &gt;80 years old, we defined SENIOR-IPI, an easily applicable prognostic index for this elderly population treated with an anti-CD20-miniCHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-based regimen. SENIOR-International Prognostic Index (SENIOR-IPI) takes into account accessible variables (number of aaIPI predictors, lactate dehydrogenase &gt; 3x Upper Limit of Normal (LDH &gt;3× ULN), albumin &lt;35 g/L and number of years over 80) and segregates patients into four risk categories. In the training cohort, SENIOR-IPI performed better than IPI, age-adjusted IPI (aaIPI) and National Comprehensive Cancer Network IPI (NCCN-IPI) for progression-free survival (PFS) and overall survival (OS). The validation cohort included 195 patients from the real-world REal world all dAta in LYmphoma and Survival in Adults (REALYSA) cohort and confirmed better performance of SENIOR-IPI than IPI, aaIPI and NCCN-IPI both for PFS (<i>C</i>-index 0.66 vs. 0.61, 0.64 and 0.61 respectively) and OS (<i>C</i>-index 0.67 vs. 0.59, 0.62 and 0.61 respectively). Restricted mean survival times at 2 and 5 years were also evaluated: at 2 years, 10 additional SENIOR-IPI points led to 3.7 and 3.6 months of survival lost, respectively, in the training and validation cohorts. Overall, SENIOR-IPI is an easily applicable and reproducible prognostic index, using only readily available clinical and biological data, which better stratifies prognosis of LBCL patients &gt;80 years old fit for age-adapted immunochemotherapy than IPI, aaIPI and NCCN-IPI.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"209 5","pages":"2073-2082"},"PeriodicalIF":3.6,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.70784","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149068905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and socio-economic disparities in chronic lymphocytic leukaemia 2014–2022: An England-wide cohort study from the UNCOVER group","authors":"Temitope Erinfolami,&nbsp;Amelia Fisher,&nbsp;Indrani Karpha,&nbsp;Yeong Lim,&nbsp;Nurunnahar Akter,&nbsp;Toyyib Abdulkareem,&nbsp;Brogan Johnston,&nbsp;Catrin Tudur Smith,&nbsp;Hilary Lindsay,&nbsp;Shaun Bowden,&nbsp;Debbie Yates,&nbsp;Lelia Duley,&nbsp;Renata Walewska,&nbsp;Stella Williams,&nbsp;David Allsup,&nbsp;Nagesh Kalakonda,&nbsp;Mark Bishton,&nbsp;Andrew Pettitt,&nbsp;Nicolas Martinez-Calle","doi":"10.1111/bjh.70765","DOIUrl":"10.1111/bjh.70765","url":null,"abstract":"<p>To re-evaluate chronic lymphocytic leukaemia (CLL) epidemiology in the era of modern therapy, data were extracted from the English National Cancer Registration Dataset (NCRD). A total of 34 427 consecutive diagnoses of CLL were recorded (2014–2022), the largest European dataset on record. In addition to known associations with age, gender-ethnicity, multivariable analysis showed incidence rate ratio (IRR) variations with government region (IRR ranging from 0.78 to 0.94 vs. London), socioeconomic deprivation (1.06 [95% confidence interval (CI) 1.02–1.10] for most vs. least deprived quintile) and IRR fall in successive calendar years (0.70 [95% CI 0.67–0.73] for 2022 vs. 2014). With a median follow-up of 74.4 months, 36.9% of patients had died, including 13.6% from blood cancer. 1-, 3- and 5-year overall survival (OS)/net survival rates were 90%/94%, 78%/87% and 67%/81%, respectively. Age, male gender, comorbidity and socioeconomic deprivation were independently associated with shorter OS and cause-specific survival (CSS), with OS-hazard ratio (HR) of 1.42 (95% CI 1.34–1.50) and CSS-HR of 1.28 (1.16–1.41) for the most versus least deprived quintiles. In addition, government region was independently associated with CSS, with HRs relative to London ranging from 0.84 (0.74–0.96) to 1.12 (0.99–1.27). Our findings reveal previously unreported disparities in CLL incidence and survival based on place of residence.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"209 5","pages":"2056-2065"},"PeriodicalIF":3.6,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.70765","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD47 promotes myeloma cell growth through JAK–STAT3/MYC signalling and is targetable by ruxolitinib","authors":"Omar Faruq,&nbsp;Deepak Iyer,&nbsp;Patrick Wang,&nbsp;Mariusz Shrestha,&nbsp;Cuihong Wei,&nbsp;Aaron D. Schimmer,&nbsp;Hong Chang","doi":"10.1111/bjh.70736","DOIUrl":"10.1111/bjh.70736","url":null,"abstract":"<p>Cluster of differentiation 47 (CD47), a ‘don't eat me’ immune checkpoint receptor, is frequently overexpressed on multiple myeloma (MM) cells and contributes to immune evasion. While its immune regulatory function is well established, the intrinsic oncogenic role of CD47 remains poorly understood. Here, we demonstrate for the first time that CD47 intrinsically promotes myeloma cell proliferation and survival by activating the JAK/STAT3–MYC (Janus kinase/signal transducer and activator of transcription 3 – MYC) signalling axis. CD47 overexpression increased cell growth, accelerated G1–M-cell cycle progression and promoted anchorage-independent colony formation, accompanied by elevated phosphorylation of STAT3 and upregulation of <i>MYC</i>, whereas CD47 knockdown produced the opposite effects. Transcriptomic analysis of patient datasets revealed that high <i>CD47</i> expression was associated with enrichment of the JAK–STAT3 and MYC pathways, and <i>CD47</i> levels positively correlated with <i>STAT3</i> and <i>MYC</i> expression, suggesting a potential regulatory interplay among these molecules. Pharmacological inhibition using the JAK1/2 inhibitor ruxolitinib (Rux) decreased cell viability, induced apoptosis and suppressed STAT3 and MYC signalling. Moreover, Rux synergized with bortezomib in myeloma cell lines and primary patient samples but spared normal cells. Collectively, these findings identify CD47 as an oncogenic driver with an intrinsic signalling function in MM and highlight the CD47–STAT3–MYC axis as a promising therapeutic target.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"209 5","pages":"2034-2043"},"PeriodicalIF":3.6,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.70736","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148756995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of chronic myeloid leukaemia complicated by SF3B1-mutant myelodysplastic syndrome","authors":"LiJun Zhou,&nbsp;ZhaoPeng Chu,&nbsp;HaiYan Zhu","doi":"10.1111/bjh.70769","DOIUrl":"10.1111/bjh.70769","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"209 5","pages":"1990-1991"},"PeriodicalIF":3.6,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148823536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the UK Myeloma Research Alliance risk profile in transplant-ineligible multiple myeloma patients treated with novel agents","authors":"Hitomi Nakayama,&nbsp;Tomonori Nakazato,&nbsp;Atsushi Takahata,&nbsp;Eriko Sato,&nbsp;Maho Kawakami,&nbsp;Keigo Okada,&nbsp;Takashi Abe,&nbsp;Toshiaki Hayashi,&nbsp;Kohtaro Toyama,&nbsp;Yasutaka Senpuku,&nbsp;Masaru Nakagawa,&nbsp;Motoki Takano,&nbsp;Keisuke Tanaka,&nbsp;Yuki Osada,&nbsp;Junichi Watanabe,&nbsp;Koh Yamamoto,&nbsp;Yasunobu Sekiguchi,&nbsp;Gaku Oshikawa,&nbsp;Yuta Kimura,&nbsp;Michihide Tokuhira,&nbsp;Ken Suzuki,&nbsp;Takayuki Ikezoe,&nbsp;Noriyoshi Iriyama,&nbsp;Katsuhiro Miura,&nbsp;Takashi Kumagai,&nbsp;Shigeo Toyota,&nbsp;Takehiko Mori","doi":"10.1111/bjh.70810","DOIUrl":"10.1111/bjh.70810","url":null,"abstract":"<div>\u0000 \u0000 <p>The heterogeneity of multiple myeloma (MM) significantly impacts treatment outcomes. Myeloma risk profile (MRP), introduced by the UK Myeloma Research Alliance, is a novel prognostic model for patients with transplant-ineligible newly diagnosed MM (TIE-NDMM) utilizing easily available clinical parameters. In this study, we evaluated the prognostic value of MRP in TIE-NDMM patients treated with novel agents. We retrospectively analysed the data of 799 evaluable MM patients diagnosed between January 2011 and January 2023, extracted from the Japan Clinical Hematology Research Group-EAST (J-CHARGE)-MM database. Overall survival (OS) differed significantly across the three MRP risk groups (<i>p</i> &lt; 0.01). The MRP risk groups remained independently prognostic when adjusted for treatment period and first-line therapy (medium vs. low: hazard ratio [HR], 1.71; <i>p</i> &lt; 0.01; high vs. low: HR, 2.61; <i>p</i> &lt; 0.01). In subgroup analyses, the MRP classification significantly predicted OS in patients treated with bortezomib-based and lenalidomide-based regimens. However, there was no difference in OS between the MRP risk groups in patients treated with daratumumab-based regimens. MRP is a robust prognostic tool for real-world TIE-NDMM patients treated with novel agents. Further studies are warranted to clarify its prognostic utility in the era of front-line anti-CD38 monoclonal antibody-based therapies.</p>\u0000 </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"209 5","pages":"2117-2126"},"PeriodicalIF":3.6,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148885746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cellular and molecular impacts of CELMoDs and IMiD on the induction of myeloid-derived suppressor cells by myeloma cells","authors":"Yui Niiyama-Uchibori,&nbsp;Taku Tsukamoto,&nbsp;Yu Inoue,&nbsp;Shotaro Chinen,&nbsp;Takahisa Nakamura,&nbsp;Hiroaki Nagata,&nbsp;Haruya Okamoto,&nbsp;Takahiro Fujino,&nbsp;Shinsuke Mizutani,&nbsp;Yuji Shimura,&nbsp;Junya Kuroda","doi":"10.1111/bjh.70787","DOIUrl":"10.1111/bjh.70787","url":null,"abstract":"<div>\u0000 \u0000 <p>To identify strategies to prevent the induction of monocytic myeloid-derived suppressor cells (M-MDSCs) in multiple myeloma (MM), we analysed molecular changes in myeloma and myeloid cells within peripheral blood mononuclear cells (PBMCs) that promote M-MDSC induction during co-culture. We then examined the effects of cereblon E3 ligase modulators (CELMoDs), iberdomide (IBER) and mezigdomide (MEZI), compared with pomalidomide (POM), on M-MDSC induction from PBMCs during co-culture with human myeloma-derived cell lines (HMCLs). Co-culturing PBMCs with HMCLs increased inflammatory, interleukin (IL)-6-Janus kinase-signal transducer and activator of transcription (JAK-STAT)3 and tumour necrosis factor (TNF)-α-associated gene expression in HMCLs, while decreasing interferon-related genes in myeloid cells. CELMoDs inhibited M-MDSC induction, with 7.5 nM IBER and 1 nM MEZI as effective as 1 μM POM. In this context, CELMoDs and POM reduced inflammatory genes, including those involved in TNF-α signalling via nuclear factor-kappa B (NF-κB), in HMCLs and lowered pro-inflammatory genes, including C-C motif chemokine ligand 5 (CCL5). Conversely, in myeloid cells, CELMoDs and POM enhanced immune-activating pathways linked to interferon responses. Furthermore, CELMoDs and POM reduced candidate soluble mediators associated with M-MDSC induction, such as migration-inhibitory factor (MIF) and IL-10, in myeloid cells and decreased IL-10 secretion from IL-10-producing HMCLs. In summary, CELMoDs effectively inhibit M-MDSC induction by altering gene expression in co-cultured HMCLs and myeloid cells, while also suppressing mediators like IL-10 and MIF.</p>\u0000 </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"209 5","pages":"2011-2023"},"PeriodicalIF":3.6,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148811653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of direct-acting antivirals in people with HIV-associated non-Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi","authors":"Michele Merli,&nbsp;Benedetta Bianchi,&nbsp;Michele Bibas,&nbsp;Davide Dalu,&nbsp;Rosa Daffini,&nbsp;Emanuele Ravano,&nbsp;Giovanni Rindone,&nbsp;Guido Gini,&nbsp;Carlo Visco,&nbsp;Maria Chiara Tisi,&nbsp;Emanuele Cencini,&nbsp;Dario Marino,&nbsp;Massimo Gentile,&nbsp;Valentina Zuccaro,&nbsp;Cristina Rovelli,&nbsp;Valentina Mazzotta,&nbsp;Cinzia Fasola,&nbsp;Vittorio Ruggero Zilioli,&nbsp;Luisa Verga,&nbsp;Carmela Pinnetti,&nbsp;Manuel Gotti,&nbsp;Francesca Gaia Rossi,&nbsp;Nicolò Rampi,&nbsp;Andrea Ferrario,&nbsp;Chiara Pagani,&nbsp;Layla Pagnucco,&nbsp;Nicla La Verde,&nbsp;Paolo Grossi,&nbsp;Alessandra Bandera,&nbsp;Luigi Marcheselli,&nbsp;Marta Coscia,&nbsp;Francesco Passamonti,&nbsp;Michele Spina,&nbsp;Luca Arcaini,&nbsp;Alessandro Re","doi":"10.1111/bjh.70793","DOIUrl":"10.1111/bjh.70793","url":null,"abstract":"<div>\u0000 \u0000 <p>Chronic hepatitis C virus (HCV) infection is common among patients with human immunodeficiency virus (HIV)-related non-Hodgkin lymphoma (NHL). Although direct-acting antivirals (DAAs) achieve high sustained virological response (SVR) rates, data on their effects in people with HIV and HCV and affected by NHL remain limited. We conducted a retrospective study of 67 consecutive NHL patients with HIV and HCV (48 diffuse large B-cell lymphoma [DLBCL]) treated at 14 Italian centres (2010–2024). All patients received concomitant anti-retroviral therapy (ART). The median age was 51 years. The majority of patients were male (91%) and people who inject drugs (70%). Most patients (94%) received curative first-line immunochemotherapy (I-CT), mainly rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). After 2016, 26 patients received DAAs (8 concurrently, 18 after I-CT). DAA toxicity was minimal, and SVR was achieved in all cases. With a median follow-up of 91 months, the 3-year overall survival (OS) was 61%. Patients treated with DAAs had better 5-year OS (81% vs. 48%, <i>p</i> = 0.035), with no difference between those who received DAAs subsequently or concurrently with I-CT. Multivariate analysis identified high age-adjusted International Prognostic Index (aaIPI), HIV score 3–6, female sex and absence of rituximab treatment as independent risk factors for OS, while DAAs had a borderline impact (<i>p</i> = 0.055). In conclusion, DAA therapy during or after I-CT is feasible, safe and highly effective in this high-risk group.</p>\u0000 </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"209 5","pages":"2083-2093"},"PeriodicalIF":3.6,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148890528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nodular amyloid light chain amyloidosis of the tongue","authors":"Nicola Sgherza,&nbsp;Laura Verga,&nbsp;Pellegrino Musto","doi":"10.1111/bjh.70826","DOIUrl":"10.1111/bjh.70826","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"209 5","pages":"1988-1989"},"PeriodicalIF":3.6,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149056651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal iron homeostasis, disorders and pregnancy outcomes","authors":"Vida Zhang,&nbsp;Elizabeta Nemeth,&nbsp;Veena Sangkhae","doi":"10.1111/bjh.70718","DOIUrl":"10.1111/bjh.70718","url":null,"abstract":"<div>\u0000 \u0000 <p>Iron is essential for a healthy pregnancy, and multiple iron-regulatory mechanisms—maternal, placental and fetal—are involved in maintaining iron homeostasis during pregnancy. Iron disorders, particularly iron deficiency anaemia, are prevalent in women of reproductive age and represent the leading cause of years lived with disability in women worldwide. During pregnancy, the prevalence of iron deficiency anaemia increases further (ranging from 12% to 80% depending on the region) and is associated with maternal morbidity and mortality, as well as adverse fetal and long-term outcomes in offspring. Despite this burden, routine screening for iron deficiency is uncommon, and early treatment prior to the development of anaemia is lacking. Although far less prevalent, iron overload is also associated with adverse outcomes. Further studies are needed to elucidate the effects of maternal iron overload on the placenta and fetus, its consequences for child development, and to inform improved management strategies for this underrecognized condition. The goal of this review is to summarize physiological iron requirements and regulatory mechanisms during pregnancy, evaluate the benefits and limitations of available biomarkers and therapies, and underscore the importance of early and repeated screening for iron deficiency throughout gestation.</p>\u0000 </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"209 5","pages":"1994-2006"},"PeriodicalIF":3.6,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148583218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}